[go: up one dir, main page]

WO2005097762A3 - 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee - Google Patents

1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee Download PDF

Info

Publication number
WO2005097762A3
WO2005097762A3 PCT/US2005/010854 US2005010854W WO2005097762A3 WO 2005097762 A3 WO2005097762 A3 WO 2005097762A3 US 2005010854 W US2005010854 W US 2005010854W WO 2005097762 A3 WO2005097762 A3 WO 2005097762A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxadiazol
ones
delta modulators
ppar delta
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/010854
Other languages
English (en)
Other versions
WO2005097762A2 (fr
Inventor
Daniel G Mcgarry
Karen Chandross
Jean Merrill
Jochen Goerlitzer
Stefanie Keil
Wolfgang Wendler
Patrick Bernardelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602005027677T priority Critical patent/DE602005027677D1/de
Priority to CA002561738A priority patent/CA2561738A1/fr
Priority to AU2005230837A priority patent/AU2005230837A1/en
Priority to BRPI0509468-2A priority patent/BRPI0509468A/pt
Priority to EP05766888A priority patent/EP1735303B1/fr
Priority to AT05766888T priority patent/ATE507226T1/de
Priority to NZ550857A priority patent/NZ550857A/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Priority to JP2007506540A priority patent/JP4813460B2/ja
Publication of WO2005097762A2 publication Critical patent/WO2005097762A2/fr
Publication of WO2005097762A3 publication Critical patent/WO2005097762A3/fr
Priority to IL178167A priority patent/IL178167A0/en
Priority to US11/535,227 priority patent/US7576109B2/en
Anticipated expiration legal-status Critical
Priority to NO20064982A priority patent/NO20064982L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)

Abstract

L'invention se rapporte à 1, 3, 4-oxadiazolones, à des composés de la formule (I) et à leurs sels, stéréoisomères, tautomères ou solvants pharmaceutiquement acceptables. Des nouveaux composés comprennent ceux de la formule (I) dans laquelle des radicaux sont tels que définis ci-après. Lesdits composés sont des modulateurs de PPAR delta et sont par conséquent utiles en tant qu'agents pharmaceutiques, notamment pour le traitement de maladies de démyélinisation et de troubles du métabolisme d'acide gras et de l'utilisation du glucose.
PCT/US2005/010854 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee Ceased WO2005097762A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT05766888T ATE507226T1 (de) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
CA002561738A CA2561738A1 (fr) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee
AU2005230837A AU2005230837A1 (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as PPAR delta modulators
BRPI0509468-2A BRPI0509468A (pt) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
EP05766888A EP1735303B1 (fr) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee
NZ550857A NZ550857A (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as PPAR delta modulators
JP2007506540A JP4813460B2 (ja) 2004-04-01 2005-03-30 ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用
DE602005027677T DE602005027677D1 (de) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
IL178167A IL178167A0 (en) 2004-04-01 2006-09-18 1,3,4-oxadiazol-2-ones as ppar delta modulators
US11/535,227 US7576109B2 (en) 2004-04-01 2006-09-26 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
NO20064982A NO20064982L (no) 2004-04-01 2006-10-31 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55841904P 2004-04-01 2004-04-01
US60/558,419 2004-04-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/535,227 Continuation US7576109B2 (en) 2004-04-01 2006-09-26 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

Publications (2)

Publication Number Publication Date
WO2005097762A2 WO2005097762A2 (fr) 2005-10-20
WO2005097762A3 true WO2005097762A3 (fr) 2005-12-15

Family

ID=34972933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010854 Ceased WO2005097762A2 (fr) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee

Country Status (17)

Country Link
US (1) US7576109B2 (fr)
EP (1) EP1735303B1 (fr)
JP (1) JP4813460B2 (fr)
KR (1) KR20060135854A (fr)
CN (1) CN100516065C (fr)
AT (1) ATE507226T1 (fr)
AU (1) AU2005230837A1 (fr)
BR (1) BRPI0509468A (fr)
CA (1) CA2561738A1 (fr)
DE (1) DE602005027677D1 (fr)
IL (1) IL178167A0 (fr)
MA (1) MA28562B1 (fr)
NO (1) NO20064982L (fr)
NZ (1) NZ550857A (fr)
RU (1) RU2375358C2 (fr)
WO (1) WO2005097762A2 (fr)
ZA (1) ZA200607851B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2365589C2 (ru) * 2004-04-01 2009-08-27 Авентис Фармасьютикалз Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (fr) 2004-05-05 2005-11-10 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
CN101273036A (zh) * 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 具有苯基的苯基-[1,2,4]-噁二唑-5-酮衍生物、它们的制备方法和它们作为药物的用途
JP5054028B2 (ja) 2005-12-22 2012-10-24 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規化合物、それらの製造および使用
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US20120020931A1 (en) * 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
EP3043789B1 (fr) 2013-09-09 2020-07-08 vTv Therapeutics LLC Utilisation des agonistes de ppar-delta pour le traitement de l'atrophie musculaire
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078313A1 (fr) * 1999-06-18 2000-12-28 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
WO2001000603A1 (fr) * 1999-06-25 2001-01-04 Glaxo Group Limited Derives de thiazol et d'oxazole et utilisation pharmaceutique de ceux-ci
WO2001017994A1 (fr) * 1999-09-08 2001-03-15 Glaxo Group Limited Antagonistes ppar oxazole

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
RU2365589C2 (ru) * 2004-04-01 2009-08-27 Авентис Фармасьютикалз Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078313A1 (fr) * 1999-06-18 2000-12-28 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
WO2001000603A1 (fr) * 1999-06-25 2001-01-04 Glaxo Group Limited Derives de thiazol et d'oxazole et utilisation pharmaceutique de ceux-ci
WO2001017994A1 (fr) * 1999-09-08 2001-03-15 Glaxo Group Limited Antagonistes ppar oxazole

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. R. HENKE ET AL.: "N-(2-Benzoylphenyl)-L-tyrosine PPAR.gamma. Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents", J. MED. CHEM., vol. 41, no. 25, 11 November 1998 (1998-11-11), pages 5020 - 5036, XP000864731 *
S. S. KULKARNI ET AL.: "Three-Dimensional Quantitative Structure Activity Relationship (3-D-QSAR) of Antihyperglycemic Agents", BIOORG. MED. CHEM., vol. 7, 1999, pages 1475 - 1485, XP002345584 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators

Also Published As

Publication number Publication date
IL178167A0 (en) 2006-12-31
DE602005027677D1 (de) 2011-06-09
CA2561738A1 (fr) 2005-10-20
NZ550857A (en) 2009-12-24
EP1735303B1 (fr) 2011-04-27
WO2005097762A2 (fr) 2005-10-20
RU2375358C2 (ru) 2009-12-10
NO20064982L (no) 2006-10-31
CN1938305A (zh) 2007-03-28
EP1735303A2 (fr) 2006-12-27
US7576109B2 (en) 2009-08-18
JP2007531763A (ja) 2007-11-08
JP4813460B2 (ja) 2011-11-09
BRPI0509468A (pt) 2007-09-11
KR20060135854A (ko) 2006-12-29
MA28562B1 (fr) 2007-04-03
RU2006138485A (ru) 2008-05-10
ZA200607851B (en) 2008-06-25
CN100516065C (zh) 2009-07-22
AU2005230837A1 (en) 2005-10-20
ATE507226T1 (de) 2011-05-15
US20070060626A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
WO2008030412A3 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
WO2005065195A3 (fr) Inhibiteurs de phenylamide et de pyridylamide de la beta-secretase, traitant la maladie d'alzheimer
WO2005097763A3 (fr) 1,3,4-oxadiazol-2-ones en tant que modulateurs des ppar delta et leur utilisation
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
WO2008054698A3 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
WO2004026863A8 (fr) Nouveaux composes de triazole et d'oxazole, inhibiteurs du facteur de croissance transformant
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
EP1784388B8 (fr) Derivés d'acide biphényloxyacétique pour le traitement de la maladie respiratoire
TW200502221A (en) Novel lactams and uses thereof
WO2005097762A3 (fr) 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee
MXPA05014201A (es) Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3.
PL1697394T3 (pl) Inhibitory COMT
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
WO2005080345A3 (fr) Derives d'imidazoline a activite antagoniste cb1
WO2003070728A3 (fr) Composes aryle substitues permettant de traiter une maladie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12006501764

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 178167

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006/07851

Country of ref document: ZA

Ref document number: 200607851

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/010935

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 11535227

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2561738

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580010054.5

Country of ref document: CN

Ref document number: 3608/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007506540

Country of ref document: JP

Ref document number: 2005230837

Country of ref document: AU

Ref document number: 1020067020431

Country of ref document: KR

Ref document number: 06098507

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2005000503

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2005766888

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005230837

Country of ref document: AU

Date of ref document: 20050330

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005230837

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 550857

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006138485

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005766888

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067020431

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11535227

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0509468

Country of ref document: BR